Molecular Diagnostics News and Research

RSS

EKF Molecular to exhibit PointMan DNA-enrichment technology at AACR 2014

EKF Diagnostics, the global in vitro diagnostics business, will be present on Booth #438 at AACR 2014, 5-9th April, San Diego.

From EKF Diagnostics 26 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Self Regional Healthcare, Clemson University expand partnership to accelerate rate of innovation in genetic medicine

A new partnership will establish formal collaboration among genetic researchers and Clemson University faculty at the Greenwood Genetic Center and Self Regional Healthcare, expanding an already successful working relationship.

24 Feb 2014

Upstream interventions may provide options to contain emerging pathogens at source

While many endemic infectious diseases of humans have been largely contained, new microbes continue to emerge to threaten human and animal health.

18 Feb 2014

Covaris introduces truXTRAC High Throughput FFPE DNA Extraction & Purification Kit at 2014 AGBT

Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.

11 Feb 2014

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

EKF, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan DNA-enrichment tech.

From EKF Diagnostics 11 Feb 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

Clinician scientist receives RPB Career Development Award to support eye research

The Harvard Medical School (HMS) Department of Ophthalmology has been granted a $250,000 Research to Prevent Blindness (RPB) Career Development Award to support eye research conducted by Jason I. Comander, M.D., Ph.D. The support will be provided over a four-year period.

22 Jan 2014

EKF Diagnostics announces major breakthrough for PointMan DNA enrichment technology

EKF, announces a major breakthrough for its PointMan DNA enrichment technology for potential use in future cancer testing and treatment.

From EKF Diagnostics 22 Jan 2014

Affymetrix gets FDA clearance to market CytoScan Dx Assay

Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.

21 Jan 2014

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead technology with Genetic Analysis of Oslo, Norway.

7 Jan 2014

AMP proposes new, service-oriented terminology for high quality laboratory testing

The Association for Molecular Pathology (AMP) released a special article in the January 2014 issue of the Journal of Molecular Diagnostics titled "Revisiting Oversight and Regulation of Molecular-Based Laboratory-Developed Tests"(LDTs).

20 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Biocartis, VIB partner to develop novel MSI biomarkers for colorectal cancer

Today Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability biomarkers for several cancers, in particular colorectal cancer.

From Biocartis 6 Dec 2013

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex C. difficile Assay Kit and the ICEPlex System have received 510(k) clearance from the United States Food and Drug Administration.

3 Dec 2013

Xagenic announces closing of $20 million Series B financing

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the close of a Series B financing totaling $20 million. The round was led by new investor Domain Associates, LLC, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund.

2 Dec 2013